Compare FLGT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | ASMB |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.3M | 442.9M |
| IPO Year | 2016 | 2010 |
| Metric | FLGT | ASMB |
|---|---|---|
| Price | $14.88 | $26.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $28.33 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 402.1K | 91.4K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,730,000.00 | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $12.18 | $638.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.46 | $11.42 |
| 52 Week High | $31.04 | $39.71 |
| Indicator | FLGT | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 37.61 |
| Support Level | $14.23 | $23.19 |
| Resistance Level | $16.76 | $27.14 |
| Average True Range (ATR) | 0.59 | 1.44 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 24.45 | 1.47 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.